[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100659820":3},{"organization":4,"outcomesModule":7,"designInfo":62,"detailedDescription":16,"studyPopulation":16,"armGroups":68,"interventions":80,"overallOfficials":86,"centralContacts":90,"locations":96,"responsibleParty":134,"collaborators":136,"id":145,"slug":146,"hasResults":147,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":16,"eligibilityCriteria":151,"healthyVolunteers":147,"sex":152,"minAge":153,"maxAge":154,"enrollmentInfo":155,"targetDuration":16,"studyType":158,"phases":159,"briefSummary":161,"conditions":162,"keywords":165,"overallStatus":99,"whyStopped":16,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":178},{"fullName":5,"class":6},"Second Affiliated Hospital, Zhejiang University, School of Medicine","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":16},[9],{"measure":10,"description":11,"timeFrame":12},"The incidence of thrombotic events","Including deep vein thrombosis (DVT), pulmonary embolism (PE), myocardial infarction, cerebral infarction and other thrombotic events","in hospital",[14,18,19,21,23,25,27,29,32,34,36,40,41,43,45,47,48,50,52,54,56,58,60],{"measure":15,"description":16,"timeFrame":17},"the incidence of deep venous thrombosis",null,"24 hour",{"measure":15,"description":16,"timeFrame":12},{"measure":20,"description":16,"timeFrame":12},"the incidence of pulmonary embolism",{"measure":22,"description":16,"timeFrame":12},"the incidence of myocardial infarction",{"measure":24,"description":16,"timeFrame":12},"the incidence of cerebrovascular embolism",{"measure":26,"description":16,"timeFrame":12},"the incidence of other thrombotic events",{"measure":28,"description":16,"timeFrame":12},"the incidence of seizure or seizure-like activity",{"measure":30,"description":16,"timeFrame":31},"The incidence of hypotension","Within 30min after TXA bolus",{"measure":33,"description":16,"timeFrame":12},"The duration of hypotension after TXA bolus",{"measure":35,"description":16,"timeFrame":12},"The incidence of acute kidney injury",{"measure":37,"description":38,"timeFrame":39},"Percentage of clot lysed at 30 min following maximum amplitude","CL30 \\\u003C 0.8% (fibrinolysis shutdown), 0.8≤CL30≤3% (normal ), and CL30 \\> 3% (hyperfibrinolysis)","3 hour after TXA bolus",{"measure":37,"description":38,"timeFrame":17},{"measure":42,"description":16,"timeFrame":17},"mortality",{"measure":44,"description":16,"timeFrame":17},"mortality of bleeding",{"measure":42,"description":16,"timeFrame":46},"Day 28",{"measure":44,"description":16,"timeFrame":46},{"measure":49,"description":16,"timeFrame":17},"Total blood product consumption",{"measure":51,"description":16,"timeFrame":17},"Red blood cell consumption",{"measure":53,"description":16,"timeFrame":17},"Fresh frozen plasma consumption",{"measure":55,"description":16,"timeFrame":17},"Platelet concentrate consumption",{"measure":57,"description":16,"timeFrame":46},"Hospital-free days",{"measure":59,"description":16,"timeFrame":46},"Ventilator-free days",{"measure":61,"description":16,"timeFrame":46},"ICU-free days",{"allocation":63,"interventionModel":64,"interventionModelDescription":16,"primaryPurpose":65,"observationalModel":16,"timePerspective":16,"maskingInfo":66},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":67,"maskingDescription":16,"whoMasked":16},"NONE",[69,75],{"label":70,"type":71,"description":72,"interventionNames":73},"Simplified Tranexamic Acid Regimen","EXPERIMENTAL","Tranexamic Acid was administered intravenously within 3 hours after injury, with a loading dose of 2 g, and the infusion was completed after more than 20 minutes without a second dose.",[74],"Drug: Tranexamic Acid (TXA)",{"label":76,"type":77,"description":78,"interventionNames":79},"Divided-Dose Tranexamic Acid Regimen","ACTIVE_COMPARATOR","Tranexamic Acid is administered intravenously within 3 hours after injury, with a loading dose of 1 g, and the infusion is completed after more than 10 minutes. The second dose of 1 g is maintained for 8 hours.",[74],[81],{"type":82,"name":83,"description":84,"armGroupLabels":85,"otherNames":16},"DRUG","Tranexamic Acid (TXA)","Tranexamic Acid",[76,70],[87],{"name":88,"affiliation":5,"role":89},"yongan xu, PhD","STUDY_CHAIR",[91],{"name":92,"role":93,"phone":94,"phoneExt":16,"email":95},"yongan xu","CONTACT","0571-87998893","xuyongan2000@zju.edu.cn",[97,113,121],{"facility":98,"status":99,"city":100,"state":101,"zip":102,"country":103,"countryCode":104,"cosmosGeoPoint":105,"geoPoint":110,"contacts":111},"the Second Affiliated Hospital, Zhejiang University School of Medicine","RECRUITING","Hangzhou","Zhejiang","310009","China","CN",{"type":106,"coordinates":107},"Point",[108,109],120.16142,30.29365,{"lat":109,"lon":108},[112],{"name":92,"role":93,"phone":94,"phoneExt":16,"email":95},{"facility":114,"status":99,"city":115,"state":101,"zip":16,"country":103,"countryCode":104,"cosmosGeoPoint":16,"geoPoint":16,"contacts":116},"Jiaxing First Hospital","Jiaxin",[117],{"name":118,"role":93,"phone":119,"phoneExt":16,"email":120},"huijie yu","0573-82519999","yhjtj88@sina.com",{"facility":122,"status":99,"city":123,"state":101,"zip":16,"country":103,"countryCode":104,"cosmosGeoPoint":124,"geoPoint":128,"contacts":129},"Third Affiliated Hospital, Wenzhou Medical University","Wenzhou",{"type":106,"coordinates":125},[126,127],120.66682,27.99942,{"lat":127,"lon":126},[130],{"name":131,"role":93,"phone":132,"phoneExt":16,"email":133},"zhanwei ruan","0577-58815881","rzwryjzyxk@wmu.edu.cn",{"type":135,"investigatorFullName":16,"investigatorTitle":16,"investigatorAffiliation":16,"oldNameTitle":16,"oldOrganization":16},"SPONSOR",[137,139,141,143],{"name":138,"class":6},"Affiliated Hospital of Jiaxing University",{"name":140,"class":6},"The Third Affiliated Hospital of Wenzhou Medical University",{"name":142,"class":6},"The People's Hospital of Quzhou",{"name":144,"class":6},"Jinhua Central Hospital","100659820","phase-4-the-safety-of-simplified-tranexamic-acid-regimen-100659820",false,"NCT07869537","The Safety of Simplified Tranexamic Acid Regimen","Simplified Versus Divided-Dose Tranexamic Acid Regimen in Patients With Traumatic Hemorrhagic Shock: A Multicenter, Randomized, Open-Label Pilot Study","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Trauma patients\n* Significant hemorrhage (systolic blood pressure \\\u003C90 mm Hg or heart rate \\>110 beats per min, or both) or clinical assessment of risk of massive transfusion (massive transfusion was defined as administration of at least 3 PRBC within the hour of admission or at least 10 PRBC within the first 24 hours)\n* who were within 3 h of injury\n* To obtain informed consent (or comply with the requirements for emergency exemptions agree)\n\nExclusion Criteria:\n\n* Known to be allergic to TXA\n* Pregnancy\n* Traumatic cardiac arrest occurring prior to or at the time of admission, or patients with a high risk of death within 3 hours of admission\n* History of thrombotic disease (such as DVT and PE, MI, stroke)\n* History of epilepsy\n* Injury time is unknown or \\> 3 hours\n* have received TXA before admission.","ALL","18 Years","80 Years",{"count":156,"type":157},60,"ESTIMATED","INTERVENTIONAL",[160],"PHASE4","Trauma causes at least 5.8 million deaths worldwide annually, accounting for 1 in 10 of all global deaths. Uncontrolled bleeding within 24 hours after trauma is the leading cause of death in trauma patients, and about one-third of patients present with trauma-induced coagulopathy on admission. Fatal severe traumatic hemorrhage is the most common preventable factor contributing to death.\n\nTranexamic acid (TXA), a synthetic lysine derivative, competitively inhibits plasminogen activation, preventing fibrin clot breakdown and thereby enhancing hemostasis and reducing blood loss. Randomized controlled trials such as CRASH-2 have confirmed that TXA significantly reduces mortality in patients with severe traumatic bleeding. TXA has therefore become a cornerstone of traumatic hemorrhage treatment, with current international guidelines recommending 1 g intravenous bolus (over \\>10 minutes) plus 1 g intravenous maintenance infusion (over 8 hours).\n\nHowever, severe traumatic hemorrhage is typically managed in high-pressure, chaotic battlefield or emergency settings, where this complex, time-sensitive, multi-step divided regimen is difficult to fully execute in real-world practice. The omission rate of the second maintenance infusion is particularly high, reaching up to 67% during prehospital-to-hospital handover. Rowell et al. showed that even with a strict research protocol, completion of the planned 8-hour in-hospital maintenance infusion was only about 70%. Previous pharmacokinetic studies found that without the second maintenance dose, 21% of patients receiving an initial 1 g dose had already failed to achieve effective plasma concentrations at hospital admission (approximately 1.5 hours post-dose). Thus, the inherent difficulty of fully executing the divided regimen may prevent patients from receiving the full benefits of TXA.\n\nTo address this, a simplified regimen of a single 2 g loading dose without maintenance infusion has been recommended in recent expert consensus statements, especially for prehospital or battlefield settings. However, these recommendations were mainly based on the 2020 Rowell et al. randomized controlled study, whose exploratory analysis suggested potential mortality reduction with the simplified regimen. That study enrolled patients with traumatic brain injury and had limited statistical power, so evidence on the efficacy and safety of the simplified regimen in patients with severe traumatic hemorrhage remains lacking. Based on the pharmacokinetic study by Grassin-Delyle et al., a single 2 g loading dose is hypothesized to maintain effective concentrations during the peak fibrinolytic period (within 3 hours post-injury), while the transient peak plasma concentration remains well below the toxicity threshold of 500 μg\u002FmL. We therefore hypothesize that, in patients with severe traumatic hemorrhage, the simplified TXA regimen is non-inferior to the divided regimen in efficacy, including bleeding control.\n\nHowever, the primary limitation of a large randomized controlled trial to verify this hypothesis is that safety concerns regarding the simplified regimen due to higher transient plasma concentrations compared with the divided regimen have not been clearly resolved. Previous systematic reviews concluded that safety events such as thrombosis and seizures are dose-dependent, and that a total daily dose not exceeding 2 g is safe. Previous pharmacokinetic studies also suggest that the transient peak concentration of the simplified regimen should be well below the toxicity threshold. Although expert consensus has recommended the simplified regimen, suggesting it can be considered safe, studies directly comparing the two regimens are lacking, particularly regarding whether the simplified regimen increases safety risks when the total dose is identical. Before conducting a larger, more definitive efficacy trial, it is also important to evaluate recruitment rates, protocol adherence, accurate sample size estimation, and other potential barriers. For these reasons, we designed this pilot study, primarily to evaluate the safety of the simplified TXA regimen compared with the divided regimen in patients with traumatic hemorrhagic shock, and the feasibility of a subsequent randomized controlled trial.",[163,164],"Trauma Coagulopathy","Hemorrhage",[166,167,168],"trauma","hemorrhage","coagulopathy","2026-10-07",{"date":171,"type":172},"2026-10-09","ACTUAL",{"date":174,"type":157},"2026-10-01",{"date":176,"type":157},"2027-04-30",{"name":5,"class":6},3]